Cipla Ltd

Indian pharma companies operating in the US are clawing back pricing power with a differentiated pipeline. Here we identify the valuation assigned to US portfolio in light of that pipeline.

Cipla outlines derisking plans for US portfolio

Centrum Broking

The company has made progress across its focus markets, said Umang Vohra, MD & Global CEO

A group company of Manipal Education and Medical Group, Stempeutics is evaluating its Stempeucel-DFU to determine if it can treat non-healing diabetic foot ulcer

Reasonable valuations with promising India business and a differentiated US portfolio bode well for the company, currently trading at ₹924.50 per share

Maruti Suzuki, Bajaj Finance, HDFC Life, L&T Tech, Oracle Financial SBI Life, Nippon India, Cipla, KPI Energy, Amines and Plasticisers

Diagnostic companies see drop in revenue, but hospitals and pharma players still in good health

After two years of underperformance, India business and niche US generics should support the segment

During the interim period, Cipla would continue to market and distribute Galvus branded products

Sub-licenses enable manufacturing to take place in India

All eyes on gAdvair opportunity which may shrink